The pandemic has also made it more difficult and scarier for some individuals to receive treatment for their substance use disorder from both treatment clinics or emergency departments, says Todd Vanderah, head of the Department of Pharmacology in the University of Arizona College of Medicine – Tucson.

Rather than see productivity plummet with undergraduates out of the lab, Michael Johnson, a microbiologist at the University of Arizona College of Medicine - Tucson, and other researchers have pivoted to focus on renewing their existing grants, analyzing neglected data, and writing up results for publication. "There's still a lot of work that can be done remotely that is valuable and contributory to the field," Johnson said.

Amanda Wilson, an environmental health sciences doctoral candidate in the University of Arizona Mel and Enid Zuckerman College of Public Health, is lead author of a recent study published in the Journal of Hospital Infection that assessed the ability of a variety of nontraditional mask materials to protect a person from infection after 30 seconds and after 20 minutes of exposure in a highly contaminated environment.

A $2.8 million grant will fund research to develop an improved therapeutic treatment for acute ischemic stroke patients that may help them recover faster with fewer long-term complications.

A unique expertise has led to a diverse research portfolio for Patrick Ronaldson, PhD, and he wouldn’t have it any other way.

A team led by the University of Arizona College of Pharmacy hopes to develop a drug to prevent or reverse this devastating neurodegenerative disorder.

CNN chief medical correspondent Dr. Sanjay Gupta interviews Dr. Richard Carmona, the 17th U.S. Surgeon General and head of the University of Arizona's Reentry Task Force, about the process of reopening a college campus amid the COVID-19 pandemic.

Dr. Emmanuel Katsanis is studying a new chemotherapy treatment for patients with blood-related cancers, such as leukemia, who undergo a particular type of bone marrow transplant procedure.

Despite the Food and Drug Administration's emergency approval of drugs such as remdesivir, there are still no strong, highly effective treatments available, especially for the sickest patients. Through a partnership with Banner Health, the University of Arizona is already running three clinical trials, with another 11 in the pipeline.